Research programme: antibacterial wound infection therapies - Atterx Biotherapeutics

Drug Profile

Research programme: antibacterial wound infection therapies - Atterx Biotherapeutics

Alternative Names: Acinetobacter baumannii combat infections therapy - Atterx Biotherapeutics; Atterx Biotherapeutics 2041; Atterx Biotherapeutics 2043; Atterx Biotherapeutics B-040405; Atterx Biotherapeutics B-070604; Atterx Biotherapeutics B-120900; B-4474; Conjucin Agents; Conjucins; Wound infections therapies - Atterx Biotherapeutics

Latest Information Update: 25 Nov 2016

Price : $50

At a glance

  • Originator ConjuGon
  • Developer Atterx Biotherapeutics
  • Class
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Wound infections

Most Recent Events

  • 17 Aug 2005 Preclinical trials in Urinary tract infections in USA (unspecified route)
  • 17 Aug 2005 Preclinical trials in Wound infections in USA (unspecified route)
  • 28 Jun 2004 This programme is available for licensing (http://www.conjugon.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top